Pancreatic Disorders & Therapy
Open Access
ISSN: 2165-7092
+44 1478 350008
ISSN: 2165-7092
+44 1478 350008
Pancreatic cancer is the fourth-leading cause of cancer deaths worldwide that considered as the malignant tumor with the poorest prognosis and the lowest survival rate. This extremely violent disease is rarely diagnosed at an early level and difficult to treat due to its resistance to radiation therapy and chemotherapy. Here, we show that the receptor for advanced glycation end products (RAGE) and its ligands, advanced glycation end products (AGEs), high-mobility group box 1 (HMGB1) and S100 protein family are required for pancreatic cancer development, angiogenesis and metastasis through up-regulation of some anti-apoptotic molecules as matrix metalloproteinase -9 (MMP-9), kinase insert domain receptor (KDR), vascular endothelial growth factor (VEGF), platelet-derived growth factor-B (PDGF-B), hypoxia-inducible factor 1 (HIF1α), signal transducer and activator of transcription 3 (pSTAT3) and nuclear factor kappa B (NF-κB). In addition to the decrease in reactive oxygen species (ROS) those favouring the cancer cell growth and metastasis. The role of RAGE in pancreatic carcinogenesis needs further studies to investigate the relationship of RAGE with other anti-apoptotic and apoptotic molecules and examine the therapeutic potentials of anti-RAGE drugs for pancreatic cancer.